Gwo-Chin Lee, MD
Orthopaedic Surgery · New York, NYNPI 1477543072
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $268,736 of the $416,499 with a category attached, or 64.5%. 29 manufacturers reported payments, led by Stryker at 28.1% of the total. Reporting peaked in 2019 at $152,793 and has fallen 54.9% since, to $68,913 in 2025. Among orthopaedic surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $893.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$117K
- Omnilife Science, Inc$91K
- Corin USA$52K
- UOC USA Inc$33K
- Ortho Development Corporation$27K
- Restor3d, Inc.$26K
- plus $70K from 23 others
Across 25 payments — averaging $6177.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Smith+Nephew$77K
- KCI USA, Inc.$77K
Across 2 payments — averaging $31,250 each. An ownership or investment interest held by the physician or an immediate family member.
- Omnilife Science, Inc$63K
What the payments were for
- Royalty or licence$25,8126%
- Consulting fees$268,73665%
- Speaking & faculty fees$2,6031%
- Travel & lodging$89,70122%
- Food & beverage$29,6487%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 146 | $117,223 |
| Omnilife Science, Inc | 156 | $91,314 |
| Corin USA | 30 | $51,902 |
| UOC USA Inc | 8 | $33,467 |
| Ortho Development Corporation | 19 | $26,732 |
| Restor3d, Inc. | 6 | $26,036 |
| Heron Therapeutics, Inc. | 7 | $24,185 |
| Medical Device Business Services, Inc. | 2 | $16,995 |
| Convatec Inc. | 7 | $10,022 |
| Regeneron | 7 | $5,090 |
| Smith+Nephew | 24 | $4,395 |
| Conformis, Inc. | 21 | $3,512 |
| Synthes GmbH | 4 | $2,622 |
| Davol Inc. | 8 | $1,219 |
| Naviswiss, Inc. | 4 | $436 |
| Orthalign Inc | 3 | $410 |
| Microport Orthopedics Inc | 1 | $174 |
| Globus Medical | 1 | $148 |
| Ferring Pharmaceuticals Inc. | 2 | $117 |
| Henry Schein, Inc. | 1 | $88 |
| Nextstep Arthropedix, LLC | 1 | $85 |
| Dynasplint Systems Inc. | 1 | $66 |
| Anika Therapeutics, Inc. | 1 | $63 |
| Onkos Surgical, Inc. | 1 | $42 |
| Pacira Therapeutics, Inc. | 1 | $40 |
| Exactech, Inc. | 1 | $40 |
| Johnson & Johnson | 1 | $31 |
| Kinamed, Inc. | 1 | $28 |
| Heraeus Medical, LLC. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRIATHLON$69,660
- MAKO$36,137
- U-Motion II$21,285
- HTX-011$18,060
- ATTUNE$16,995
- CORAIL$16,995
- RECLAIM$16,995
- SIGMA$16,995
- OMNIBotics 3.0$16,670
- U2 PF+$8,839
- ACCOLADE$6,408
- AQUACEL$6,256
- Zynrelef$6,125
- NEW PRODUCT DEVELOPMENT$4,759
- TRITANIUM$3,750
- AQUACEL AG$3,750
- U2 and USTAR II$3,000
- Journey II XR$2,153
- Actera Hip Stem$2,081
- TRIDENT$2,000
How this compares
$416,499 in reported general payments places this provider in the 95th percentile of 1,079 orthopaedic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 34 | $589 |
| Meloxicam | 65 | $318 |
| Pantoprazole Sodium | 17 | $181 |
| Oxycodone Hcl | 21 | $157 |
| Amoxicillin | 40 | $62 |
| Tramadol Hcl | 26 | $61 |
| Clindamycin Hcl | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in New York
- Anthony RomeoNew York$26.8M
- Lawrence LenkeNew York$26.8M
- Edwin SuNew York$13.2M
- William RicciNew York$11.6M
- Steven HaasNew York$11.3M
- Giles ScuderiNew York$10.7M
- Joseph ZuckermanNew York$9.9M
- Evan FlatowNew York$9.6M
- Bradford ParsonsNew York$9.4M
- Geoffrey WestrichNew York$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.